HER-2 overexpression in breast cancer is a marker for treatment resistance and orchestrates distinct tumour biology. Our group developed novel, very stable linkers for labeling trastazumab with 64Cu for in vivo imaging of HER-2 breast tumours. In a separate, but related study, the metabolic activity and hypoxic status of HER-2 breast tumours was also examined. These studies indicated that HER-2 status could be identified non-invasively with 64Cu, which has a suitable life-time for antibody based studies, and that HER-2 expression is associated with a cellular phenotype that uses oxidative phosphorylation and glycolysis simultaneously to meet its metabolic requirements.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.